Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $40.00 at Robert W. Baird

Enliven Therapeutics (NASDAQ:ELVN) had its target price boosted by Robert W. Baird from $32.00 to $40.00 in a research report released on Friday morning,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $37.00 price objective on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.

Enliven Therapeutics Stock Performance

NASDAQ ELVN opened at $24.90 on Friday. The company has a market capitalization of $1.18 billion, a P/E ratio of -12.99 and a beta of 1.08. The stock has a 50 day moving average price of $26.28 and a 200-day moving average price of $24.02. Enliven Therapeutics has a one year low of $9.80 and a one year high of $30.03.

Insider Activity

In other news, CFO Benjamin Hohl sold 6,250 shares of the stock in a transaction on Monday, October 28th. The stock was sold at an average price of $28.56, for a total transaction of $178,500.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Joseph P. Lyssikatos sold 847 shares of the firm’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $30.00, for a total value of $25,410.00. Following the sale, the insider now directly owns 1,015,188 shares in the company, valued at approximately $30,455,640. The trade was a 0.08 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 152,195 shares of company stock valued at $4,091,454. 29.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ELVN. Janus Henderson Group PLC grew its holdings in Enliven Therapeutics by 74.8% in the first quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock worth $12,604,000 after purchasing an additional 305,397 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Enliven Therapeutics by 49.2% in the second quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock worth $2,667,000 after acquiring an additional 37,632 shares in the last quarter. First Turn Management LLC purchased a new stake in shares of Enliven Therapeutics during the second quarter worth about $9,657,000. American Century Companies Inc. increased its holdings in shares of Enliven Therapeutics by 44.7% during the second quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock valued at $646,000 after acquiring an additional 8,540 shares in the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Enliven Therapeutics in the 2nd quarter valued at approximately $322,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.